MWNA
ONCE

Marshall Wace North America’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Marshall Wace North America’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6,567
Closed -$358K – 1740
2018
Q3 		$358K Buy
+6,567
New +$449K ﹤0.01% 756
2017
Q4 		– Sell
-138,022
Closed -$12.3M – 1733
2017
Q3 		$12.3M Buy
+138,022
New +$10.5M 0.08% 314

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Marshall Wace North America's ONCE Position: Q4 2018 in Review

Marshall Wace North America sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2018, closing a stake of 6,567 shares — an estimated $358K sold.

Marshall Wace North America first reported a position in ONCE in Q3 2017 and held it in 2 quarters. The position peaked at $12.3M in Q3 2017. 157 funds tracked by Wall St. Rank hold ONCE as of Q4 2018.

  • Marshall Wace North America reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Marshall Wace North America sold 6,567 Spark Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $358K.
  • Marshall Wace North America first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2017 and held it in 2 quarters.
  • Marshall Wace North America's Spark Therapeutics, Inc. Common Stock position peaked at $12.3M in Q3 2017.
  • 157 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Marshall Wace North America's 13F filing for Q4 2018, filed 14 Feb 2019.